- Powerful and effective treatment
of the pathogens of greater concern1-3
- Provides long-lasting tear concentrations4-6
- The first and only topical ophthalmic chlorofluoroquinolone1
- BESIVANCE® is a dual-halogenated
fluoroquinolone that provides potent
inhibition of bacterial DNA replication1
- BESIVANCE® is a dual-halogenated
Besivance® (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenza, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa *, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.
Besifloxacin is a dual halogenated
fluoroquinolone antibiotic that provides potent
inhibition of bacterial DNA replication.
- BESIVANCE® is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
- As with other anti-infectives, prolonged use of BESIVANCE® may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
- Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE®
- The most common adverse event reported in 2% of patients treated with BESIVANCE® was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
- BESIVANCE® is not intended to be administered systemically. Quinolones administered systemically have been associated with hypersensitivity reactions, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.
- Safety and effectiveness in infants below one year of age have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
Please click here to view the BESIVANCE® full prescribing information.
References: 1. BESIVANCE Prescribing Information, April 2009. 2. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159-1169. 3. DeCory HH, Clinical Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE, Annual Meeting of the Association for Research in Vision and Ophthalmology 2012; May 6-10, Fort Lauderdale, FL: 1 4. Data on File, CSR 424 2008, 424: 1-82, Bausch & Lomb Incorporated. 5. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335-343. 6. Haas W, Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clinical Ophthalmology 2011; 5: 1369-1379.
©2014 Bausch & Lomb Incorporated. US/BES/13/0005 (1)